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DEBATE
Sperm DNA fragmentation testing: To do or not to do?
Comment by: Khaldoun Sharif
Reproductively speaking, the package carried in the sperm
is the paternal DNA, which upon union with the oocyte will
potentially lead to the creation of an embryo and consequently
a baby. Therefore, it is both biologically plausible and clini-
cally tempting to assume that testing sperm DNA damage
(the so-called fragmentation) will increase our understanding
of fertility problems and help us decide the most suitable treat-
ment for them.
A lot of work has been done in this ﬁeld in recent years, and
a search in Google Scholar for ‘‘sperm DNA fragmentation’’
between the years 2001 and 2012 showed 2390 publications,
in contrast to only 20 such publications between 1991 and
2000.
So given this amount of published work, the biological
plausibility and the clinical appeal of the idea, one would think
that incorporating sperm DNA fragmentation testing in clini-
cal practice is a given. Well, the experts disagree, and in this
debate we have asked two world-renowned experts in the ﬁeld
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The place of sperm DNA fragmentation
testing in current day fertility
management
Comment by: Sheena E.M. Lewis
1. We know traditional semen analysis tells us little-why do we
keep using an inadequate batch of tests?
Male infertility is the commonest cause of infertility yet we keep
sidetracking it. It contributes to nearly 50% of the 15% of
couples of reproductive age. As a result of population aging
and adverse changes in our lifestyle, infertility increases (with
4%more couples seeking ART per year) while we are only mak-
ing a marginal improvement in pregnancy and birth rates after
30 years of trying. ART year on year (average live birth rate
21%, (6)). Why do we accept this as good enough for our pa-
tients?Why canwe not improve? I believe that onemajor reason
is that we do not understand the causes of male infertility at the
molecular level. Furthermore, since the advent of intracytoplas-
mic sperm injection (ICSI), there has been no incentive to devel-
op pharmaceutical therapies for male infertility. We believe we
can get around the problem rather than solving it. But let us
remember, in 30% of cases, women are subjected to invasive
procedures for ICSI although they are fertile. Conventional
semen analysis remains the only routine test to diagnose this
condition although it cannot discriminate between the sperm
of fertile and infertile men (10). This belief is reﬂected in the
shifting values for normality (all ‘normal’ values are now
lower) in the 5th edition of the WHO manual, (18) compared
to previous WHO guidelines. Further, only 1% of sperm even
reach the oocyte in vivo, so why would we expect an analysis
of the widely ranging gross parameters of the whole ejaculate
to give strong discriminatory information? That approach is
simply not scientiﬁc. All that a semen analysis can do is identify
men whose chance of achieving a natural pregnancy is very low
i.e. they have few or no sperm. . .!
1.1. Why test sperm DNA?
Over the last decade, a plethora of studies (11) have conﬁrmed
that sperm DNA damage testing has strong associations with
every early fertility check point. These include impaired fertiliza-
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tion, slow early embryo development, reduced implantation,
miscarriage and, in animal studies, birth defects in the offspring.
Childhood cancers have also been associated with oxidative
damage to sperm DNA as a consequence of paternal smoking.
What couples would beneﬁt from a sperm DNA test? To
answer this question, we must ﬁrst ask another. Why are we
testing sperm DNA? The answer is so that we may guide cou-
ples with low damage to intrauterine insemination (IUI) or
in vitro fertilization (IVF) and guide those couples with high
DNA damage to ICSI (reasons why these sperm are successful
after ICSI will be explained later). So, the only group who
would not beneﬁt from testing is that of couples with oligo-
astheno-terato-zoospermia as there is no treatment other than
ICSI for them.
As for all other categories of couples, spermDNA testingwill
provide essential information onwhich clinics can guide couples
to bespoke treatment for their particular needs. These include
couples with unexplained infertility, men with normal semen
by semen analysis prior to embarking on IVF, couples who have
had unsuccessful IVF and couples who have had miscarriages.
1.2. What tests are currently available for sperm DNA damage?
For a spermDNA test to be clinically useful it must have strong
predictive capacity for pregnancywith little overlap between fer-
tile and infertile samples. The four tests most often used today
are the Comet assay, SCSA, the terminal transferase dUTP nick
end labeling (TUNEL) assay, and the SpermChromatinDisper-
sion (SCD or Halo) test. SpermDNA tests are all different. Just
as apples are NOT oranges! Both are fruits but they are very dif-
ferent types of fruits. The current range of sperm DNA tests
measure different aspects of DNA damage and have different
sensitivities. That is why combining them in a meta- analysis
(19) must be viewed with a little caution.
2. The Sperm chromatin structure assay
The SCSA is a ﬂuorescence cell sorter test which measures the
susceptibility of sperm DNA to denaturation after exposure to
heat or acid conditions. A strength of SCSA is its ability to
measure large numbers of cells rapidly. This gives it robust sta-
tistical power. It measures only single stranded fragments, and
has demonstrated repeatedly strong associations between na-
tive, although not DGC, sperm and ART outcomes. In terms
of sensitivity, it can detect sperm DNA damage in 20% of
unexplained couples. However, the SCSA test has been tried
and tested over many years and has a standardized protocol
for all users. This has reduced inter-laboratory variation and
allowed comparison of studies from different groups globally.
The clinical threshold is a DNA fragmentation index (DFI) of
30%- that means 30% of the sperm have damage (with quan-
tiﬁcation into moderate or high damage) and 70% have no
detectable damage. Couples with >30% damage are more
likely to have success with ICSI than IVF.
3. The TUNEL assay
The TUNEL assay detects ‘nicks’ (free ends of DNA) by incorpo-
rating ﬂuorescently stained nucleotides. This allows the detection
of single and double stranded damage. The cells can be assessed
either microscopically or by ﬂow cytometric (FCM) analysis. A
disadvantage of the assay is its many protocols, whichmakes com-
parison between laboratories almost impossible and explains its
many clinical thresholds. Recently, Aitken’s group (2011) (14)
has improved the TUNEL assay by including a preliminary step
of DDT to relax the whole chromatin structure and allow access
to all ‘nicks’. They have also added a viability stain so that DNA
damage is measured only in live sperm. This has eliminated a pre-
vious inaccuracy of measuring damage (often at high levels) in
dead cells. The TUNEL has major potential but robust clinical
thresholds have yet to be established.
4. The sperm chromatin dispersion (Halo) test
The Halo test is a ‘cheap and convenient’ kit form of sperm
DNA testing. It is a simple and inexpensive assay, available
in fertility labs for in house use. Unlike all the other tests, it
measures the absence of damage rather than the damaged
DNA in sperm. One limitation of the assay is that its low-den-
sity nucleoids are relatively faint, with less contrasting images.
To date, correlations have been observed between DNA and
other sperm parameters, although few correlations between
sperm DNA damage and ART outcomes have been estab-
lished with the Halo test, even in large studies.
5. The Comet assay
The comet assay is a second generation sperm DNA test. Un-
like the other three tests, it quantiﬁes the actual amount of
DNA damage per sperm. As the mass of DNA fragments
stream out from the head of unbroken DNA, they resemble
a ‘heavenly comet’ tail, hence the name of the assay. One ma-
jor advantage of this assay is that it uses only 5000 sperm, so is
suitable for the assessment of small samples left over from clin-
ical use, or for samples where only a few sperm are available.
The Comet assay can measure both single and double strand
breaks, and with an additional step can measure even altered
bases. This is useful, because we do not yet know which types
of DNA damage are most deleterious to male fertility. The Co-
met is sensitive, repeatable and capable of detecting damage in
every sperm (even those of fertile donors). Since 2010, clinical
thresholds for the diagnosis of male infertility and the predic-
tion of successful IVF have been established.
5.1. Unexplained infertility is unexplained no more
As we all know, unexplained infertility is a very unsatisfactory
diagnosis for couple and clinic alike. In our latest study we
have shown that 80% of couples diagnosed with idiopathic
infertility have sperm DNA damage (>25% damage per
sperm). This suggests that sperm DNA damage is the cause
of infertility in a substantial number of men if we compare
these levels of damage we reported in sperm of donor men with
proven fertility (15). We also reported that 40% of these cou-
ples had such high sperm DNA damage (>50%) that IVF had
very poor success for them. Couples with idiopathic infertility
had lower live birth rates following IVF (15%) compared with
couples undergoing IVF (20%) following the detection of a fe-
male problem. This ﬁnding is also reﬂected in disappointedly
low effectiveness of the IVF treatment when measured as the
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cumulative incidence of live delivery after commencing IVF
treatment. Previously we would have expected these couples
to have high success rates since we could detect no anomalies
but we now know this is a mis-diagnosis. Offering them IVF or
in some cases (IUI) without DNA testing can lead to treat-
ments with very low chances of success. From the clinic’s view-
point, using IVF for these couples is a poor choice too as it
reduces their overall IVF success rates.
5.2. The beneﬁts of sperm DNA testing
For all couples having IVF, after diagnosis with a female factor,
sperm DNA fragmentation also has a close inverse relationship
with live birth rates. Our latest results (15) were based on divid-
ing couples into groups depending on the severity of their sperm
DNA damage. Those with spermDNA fragmentation (<25%)
had live births of 33% following IVF treatment. In contrast,
couples with sperm DNA fragmentation (>50%) had a much
lower live birth rates of 13% following IVF treatment.
If we were to incorporate this new information into routine
clinical care, we could direct these patients straight to ICSI
treatment thus avoiding loss of valuable biological time, cost
of failed cycles and heartache after repeatedly unsuccessful cy-
cles of IVF treatment.
Further compelling reasons for testing sperm DNA come
from its strong associations with miscarriage. A systematic re-
view and meta-analysis (16) of 16 cohort studies (2969 cou-
ples), 14 of which were prospective studies which examined
the effect of sperm DNA damage on miscarriage rates was per-
formed. We used the terms ‘DNA damage’ or ‘DNA fragmen-
tation’ combined with ‘miscarriage’, ‘abortion’ or ‘pregnancy’
to generate a set of relevant citations. Sub-group analyses were
performed by the type of DNA damage test, whether the
sperm examined were prepared or raw ejaculate and IVF or
ICSI treatment. The meta-analysis showed a signiﬁcant in-
crease in miscarriage in patients with high DNA damage com-
pared with those with low DNA damage (Risk Ratio
(RR) = 2.16 [1.54, 3.03], P< 0.00001).
5.3. A fresh look at the ‘evidence’ against Sperm DNA damage
testing
The meta- analyses of Zini and Sigman (19) and of Collins
et al. (5) were the ﬁrst to bring all the sperm DNA data to-
gether and highlight the substantial body of work. However,
we must view their conclusions with caution due to the signif-
icant heterogeneity of different assays, different female ages,
some sperm from raw semen, some from prepared sperm,
different ART endpoints and different thresholds for clinical
signiﬁcance. The primary objective of the ESHRE position pa-
per in 2009 was not to support or refute clinical DNA testing.
It was written as an overview of the maturational vulnerabili-
ties of sperm DNA and a mechanistic look at DNA damage
and repair. The section on clinical testing was less than 10%
of the content. In addition, as with the meta- analysis by Zini
and Sigman (19), it did not include Comet data. The objective
of the ‘Cochrane’ review by Van Rumste et al. (17) was to
investigate if live birth rates were better with ICSI than IVF
in couples with non male sub-fertility. The review began with
ten randomized controlled trials but all but one study were
excluded for design reasons. The one study as we know was
from Bhattacharya et al., and published in The Lancet in
2001 (4). However, the numbers of couples included in this
one study are relatively small (n= 224 in IVF group,
n= 211 in ICSI group). Even this study did not give live birth
rates or miscarriage rates. The couples were identiﬁed as
having non-male sub-fertility at time of study (2001) by semen
parameters that are now viewed as neither predictive of diag-
nosis of male infertility nor useful in predicting ART outcome.
As with all Cochrane reviews it concluded that further studies
are needed.
The American Society of Reproductive Medicine (ASRM)
(2) has recently released a position paper for consultation
(2013) (3). In my opinion, this paper presents a negatively
biased and unbalanced overview. It dismisses the ﬁndings of
around 100 papers in high impact journals over the last
30 years (11) as ‘insufﬁcient evidence’ and turns the range of
different sperm DNA tests measuring different aspects of
DNA damage into a weakness rather than accepting it as the
strength it is. My speciﬁc objections include the ASRM
requirement of Level 1 evidence of quality from randomized
controlled trials prior to clinical use. This is in stark contrast
to the approach adopted to ICSI in 1995, when it became a
routine publically funded fertility treatment on a global scale
without any human trials at all. Further, I would direct you
to the paper by (9) followed by the letter by Richard Legro
in Fertility and Sterility in December 2012 (12) commenting
on the quality of RCTs over 2006–2011 in ﬁve leading human
reproduction journals and pointing out that incomplete out-
come data and inadequate allocation concealment led to bias
in almost 50% of them.
In terms of ASRM Level 11 requirements, the sperm DNA
test designed in our lab; the SpermComet; conforms to all of
them. These data result from studies performed on large num-
bers of over 500 couples. These couples were consecutive cases
and were controlled for female factors. The primary endpoints
were live birth rates. However, despite numerous reviews
showing its serious limitations of semen analysis and evidence
of the stronger repeatability, sensitivity and speciﬁcity of
sperm DNA damage testing, ASRM still supports the contin-
ued use of semen analysis alone for diagnosis. Further, the
level of precision that ASRM requires, can never come from
one test. Fertilization is a multi-factorial process and a success-
ful ART outcome depends on many other traits of sperm qual-
ity and function, as well as the inﬂuences of the oocyte, uterine
receptivity and maternal immune system competence. Finally,
the ASRM document, having begun by criticizing DNA test-
ing as measuring different aspects of DNA damage and there-
fore being non-uniform, then criticized DNA testing for being
non speciﬁc ‘ for not providing an indication of speciﬁc DNA
sequences that may be affected’. As no one yet knows what as-
pects of DNA damage at large, nor any speciﬁc sequences that
are responsible for ‘male infertility’, neither of these opposing
criticisms are based on sound science.
5.4. Reasons why sperm with poor DNA are successful in ICSI
One question that has exercised my mind much upon analyz-
ing the data is ‘Why do sperm with DNA damage not reduce
success following ICSI?’
I have four hypotheses (all based on sound studies) to ex-
plain this:
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Firstly, up to 30% of women having ICSI have no detect-
able problems. They may be fertile and their oocytes may have
more capacity to repair DNA damage even if the injected
sperm is of poor quality. This is supported by the ﬁndings of
Meseguer et al. (13), where high quality oocytes from donors
offset the negative impact of sperm DNA damage on preg-
nancy. Further, the study of Devroey et al. (7), shows that sig-
niﬁcantly fewer good quality embryos were available for
transfer from women more than 40 years of age compared to
the younger group, reﬂecting better DNA repair capacity of
oocytes from young women. This is relevant in that women
undergoing ICSI are often younger than those undergoing
IVF as their cause of infertility has been diagnosed earlier
and they have not spent time undergoing failed intrauterine
insemination or IVF before embarking on a cycle of ICSI. Sec-
ondly, in ICSI, the gametes are not subjected to prolonged cul-
ture so the sperm may have less damage than those exposed to
culture media overnight, as in IVF procedures. The recent ma-
jor study from Dumoulin et al. (8) shows that even the birth
weight of IVF babies can be markedly inﬂuenced by minor dif-
ferences in culture conditions. In contrast to IVF, ICSI sperm
are injected into the optimal environment of the oocyte within
a few hours of ejaculation. This may protect them from labo-
ratory induced damage. Thirdly, much sperm DNA damage is
caused by oxidative stress (1) and so these sperm are producing
reactive oxygen species. If they are used in IVF, the oocyte
may be exposed to oxidative assault during the overnight incu-
bation from these 0.5 million sperm. In ICSI, the oocyte is
protected from this attack and can use its energies to repair
the damage in the sperm immediately following fertilization.
Finally, there is now evidence that embryos created from
sperm with high DNA damage are associated with early preg-
nancy loss (reviewed by Robinson et al. (16) so ICSI success
rates are sometimes affected adversely by sperm DNA damage,
but at a later stage.
5.5. Limitations of sperm DNA testing
The major limitation of testing for sperm DNA damage is
that the assay renders the tested sperm unsuitable for clinical
purpose. In an effort to overcome this problem, a number of
non-invasive tests have been developed and their
correlation with DNA damage assessed. These novel test
include Birefringence, Intracytoplasmic morphologically
selected sperm injection (IMSI) and Hyaluronic acid-selection
of sperm for ICSI. If these tests can help embryologists
choose sperm with low DNA damage for ART, a major step
forward in sperm selection will be achieved, but presently this
is not the case.
5.6. Why wait? The beneﬁts for clinics and couples
Couples will avoid the loss of valuable biological time, the cost
of failed cycles and the heartache of repeatedly unsuccessful
cycles of IVF treatment. Unexplained couples will get a diag-
nosis and thus directs to the best treatment for them. Happier,
better informed couples will spread the word of their clinic’s
success.
Clinics will have improved IVF success rates, a scientiﬁc
rationale for using ICSI and additional revenue from appro-
priate male fertility testing. Their greater success rates will help
them retain their patient bases (with couples attending for their
next child!).
Alas, although some of these novel biomarkers (particularly
sperm DNA testing) have increasingly robust data to support
them, there is still a reluctance to incorporate them into rou-
tine clinical care. While this inertia continues and our tradi-
tional tests prevail, it seems unlikely that success rates in the
treatment of male infertility will improve and success rates will
be doomed to mediocrity.
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Andrology is desperate for a new assay –
Let us make sure we get it right this
time . . .
Comment by: Christopher L.R. Barratt,
Steven A. Mansell
Although the diagnostic and predictive value of traditional
semen parameters is limited, two facts are clear: (1) at the low-
er ends of the spectrum, e.g. low concentrations of motile sper-
matozoa, there are signiﬁcantly higher chances of sub fertility
(9,11) (2) except in rare cases values above these limits of se-
men analysis provide minimal diagnostic clarity (14). Conse-
quently, semen analysis is very helpful, but andrology
requires more robust sophisticated functional assays to be
placed in the patient’s pathway to assist/change management
decisions. Unfortunately, the search for this Holy Grail has
been littered with false dawns (2,13) continually blighted by
two key problems (1) poor technical and methodological con-
trol of purported assays (2) low quality clinical trial informa-
tion exampled by poor design often accompanied by low
numbers. Not surprisingly, the resultant data often produce
conﬂicting results.
Two key questions arise: will the testing of DNA and its
packaging in the human spermatozoon be an important tool
in the armamentarium? Is it not already (3)? We suggest the
answers here are yes and no, respectively.
The assessment of DNA integrity in the spermatozoon is
not new. In 1980, a landmark publication by Don Evenson
suggested that DNA integrity may be a useful and potentially
independent marker of fertility for both animals and men (8).
Signiﬁcant data are now available to suggest that higher levels
of DNA damage is present in men with severe sperm defects
and is an indication of a potentially negative impact on both
natural and assisted conception outcomes (4). So why do we
answer no to the second question? Simply, aside from a rela-
tively low (but signiﬁcant negative) inﬂuence of high levels of
DNA on miscarriage (15), three comprehensive reviews of
the clinical data concluded that the signiﬁcance of sperm
DNA integrity assessment for natural and ART remains un-
clear (7,4,16). Routine testing is not supported. This has been
reinforced recently by the clinical practice guidelines produced
by the British Fertility Society (19). The BFS concludes that
‘there is evidence of a relationship between sperm DNA damage
and either semen parameters and/or outcome of assisted concep-
tion. However, reports conﬂict and depend largely on the labora-
tory test utilized. Results are unlikely to alter patient
management’. The draft document presented by the American
Society for Reproductive Medicine (1) on ‘The clinical utility
of sperm DNA integrity testing: a guideline’ concurs with these
conclusions. Its ﬁnal recommendation is: ‘there is insufﬁcient
evidence to recommend the routine use of sperm DNA integ-
rity tests in the evaluation and treatment of the infertile couple
(Evidence Level B)’.
These are powerful, consistent and persuasive conclusions.
But why is this so?Unfortunately assessment ofDNA is affected
by the three key problems identiﬁed for sperm function testing.
Firstly clear technical difﬁculties of performing the three key as-
says used to test DNA integrity in sperm – SCSA, TUNEL and
Comet have affected their clinical usefulness.However, rigorous
attention to detail and deﬁned methods now exists for all these
methods, e.g. see (12) for TUNEL. Application of robust proto-
cols will, hopefully, minimize future methodological challenges.
Secondly, to date the clinical evidence is based on relatively low
numbers and poorly designed trials. Surprisingly, in this area
there are a large percentage of uncritical reviews compared to
primary data which distort the ﬁeld (3). In 2012 for example
there was only one high quality clinical study examining out-
comes for IVF/ICSI using relatively large numbers (18). This
is very disappointing and unacceptable. No progress will be
made if this is not urgently addressed. Thirdly, it has been un-
clear where the assays (when validated) ﬁt within the patient
pathway. For example, diagnostic tests can be used as replace-
ment, triage or add-on with their usefulness being dependent
on a large number of factors (6). A critical factor will be cost
effectiveness. Two examples sufﬁce here. Mitchell and col-
leagues showed that the TUNEL assay was highly correlated
to sperm viability (12) demonstrating that a simple viability as-
say could effectively replace an expensive estimate ofDNAdam-
age. Improved methodology in the TUNEL assay now allows
assessment ofDNAdamage in live cells – a substantial improve-
ment. A second example is provided by a study comparing pro-
gressive motility and DNA assessment for IVF success where it
was concluded that DNA assessment was more signiﬁcant.
However, close examination of the data shows this to be a rela-
tively small difference and it is questionable if this is actually cost
effective (17). Future studies in cost effectiveness clearly need to
establish the additional role ofDNA integrity assessment along-
side a high quality semen assessment (See (19)).
For the ﬁeld to progress we must address the above points.
These are not new (10) or speciﬁc to reproductive medicine (5).
However, to date, DNA damage assays have not been evalu-
ated in a critical manner and, quite simply, they need to be.
We are very hopeful that this will occur and DNA assessment
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